ethicon Archives - Page 2 of 3 - Medical Design Sourcing

CMR Surgical and J&J are partnering on surgical robotics

Versius surgical robotics systems [Image courtesy of CMR Surgical]CMR Surgical announced today that Johnson & Johnson MedTech’s Ethicon business will work with CMR to sell its Versius surgical robotics systems in select markets.

The collaboration involves commercial teams from the two companies working together. They’ll focus on selling to select hospitals in Italy, France, Germany and Brazil.

“By entering into this collaboration agreement with Ethicon in select markets, CMR believes that this combination of expertise in minimal access surgery and digital innovation will deliver an optimized offering to customers” CMR Surgical CEO Per Vegard Nerseth said in a news release. “CMR looks forward to progressing this agreement in strategically important regions as CMR continues to rapidly expand on a global scale.”

The news comes only weeks after the Cambridge, U.K.–based surgical robotics upstart announced that it had inst…

J&J MedTech names new innovation and R&D head

Ahmet Tezel will serve as Johnson & Johnson MedTech’s global head of medtech innovation and R&D. [Photo courtesy of J&J MedTech]

Johnson & Johnson MedTech today announced the promotion of Ahmet Tezel, Ph.D., to the position of Company Group Chairman and Global Head of MedTech Innovation and R&D.

Tezel will replace Peter Shen, Ph.D., who will retire from the role at the end of this year after a J&J career spanning more than 25 years.

Tezel will join the Medtech global leadership team and report to J&J MedTech EVP and Worldwide Chair Ashley McEvoy as the unit focuses on making its products and services “smarter, less invasive, and more personalized,” the company said in a news release.

RELATED: Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders

Tezel currently serves as worldwide VP of R&D for J&J Me…

J&J settles big Australian pelvic mesh case

[Image from Unsplash]Johnson & Johnson (NYSE: JNJ) has settled an Australian pelvic mesh class action suit for AU$300 million (roughly U.S. $205 million), according to media reports.

Shine Lawyers, which handled the suit, confirmed the settlement. It still requires court approval. More than 11,000 claimants in Australia had sought relief, according to Reuters.

In a statement shared with MassDevice by a spokesperson, Johnson & Johnson and its Ethicon subsidiary said that pending Federal Court approval, they are pleased to reach a settlement that “provides certainty and a path forward for eligible Australian patients.”

The statement added: “Ethicon empathizes with all women who experience medical complications related to pelvic organ prolapse or stress urinary incontinence. These are extremely complex medical conditions, and Ethicon has strived to support the availability of treatment options for women with these conditions.” Read more

16 surgical robotics companies you need to know

Intuitive remains the dominant surgical robotics company, but corporations ranging from Medtronic to Vicarious Surgical look to compete. The Da Vinci Xi robotic surgery system. Intuitive continues to dominate the space. [Image courtesy of Intuitive]Robotic-assisted surgery remains one of the hottest spaces in medtech. Intuitive, which pioneered the field in the 1990s and early 2000s, continues to innovate. At the same time, a host of other companies are looking to compete.

Companies making headlines in the robotic surgery space over the past year include:

Company Robotic system(s) Intuitive Surgical Da Vinci Xi, Da Vinci X, Da Vinci SP, Ion Medtronic Hugo Johnson & Johnson Monarch, Velys, Ottava Stryker Mako Siemens Healthineers’ Corindus CorPath GRX Vicarious Surgical Beta 2 Titan Medical Enos Asensus Surgical Senhance Moon Surgical Maestro Momentus Surgical Anovo Virtual Incision MIRA Stereotaxis Genesis RMN, Vdrive, Niobe Monteris …

Ethicon launches next-gen surgical stapler

The next-gen Echelon 3000 surgical stapler [Image courtesy of Johnson & Johnson’s Ethicon]Johnson & Johnson’s Ethicon today announced the U.S. launch of its next-gen Echelon 3000 stapler.

The Echelon 3000 is digitally-enabled and provides surgeons with simple, one-handed powered articulation, according to the Johnson & Johnson (NYSE:JNJ) company.

The surgical stapler’s creators designed it with 39% greater jaw aperture and a 27% greater articulation span. The idea was to give surgeons better access and control over each transection. The software then provides real-time haptic and audible device feedback so that surgeons can make critical adjustments during procedures.

“Surgical complications often stem from difficult-to-access anatomy and compromised tissue, which this next generation Echelon stapler is specifically designed to address,” said Tom O’Brien, worldwide president of Endomechanical at Ethicon.

<…

FDA clears J&J’s Ethicon’s Monarch surgical robot for urology procedures

[Image from Auris Health’s website]Johnson & Johnson MedTech (NYSE:JNJ) company Ethicon announced today that its Monarch robotic surgery platform received FDA 510(k) clearance.

Ethicon’s Auris Health subsidiary received the FDA clearance for Monarch for endourological procedures, making it the first and only multispecialty, flexible robotic solution for use in both bronchoscopy and urology.

The company said in a news release that it designed the Monarch robot-assisted surgical platform to enable urologists to reach and visualize areas within the kidney with precision and control. The system offers one platform for supporting both ureteroscopic and percutaneous nephrolithotomy (PCNL) procedures.

“Monarch reduces the complexity of gaining high-quality percutaneous access and aids stone clearance efficiency through simultaneous fragmentation and suctioning of stones with robotic assistance,” University of Southern Cali…

Johnson & Johnson must face former Auris Health shareholders’ fraud lawsuit

[Image from Unsplash]A Delaware judge has denied Johnson & Johnson’s motions to dismiss a fraud lawsuit filed by former shareholders of Auris Health, who alleged that J&J executives misrepresented their intentions for the robotic surgery company when they acquired it for $3.4 billion in 2019.

Acting as the representative of the former Auris shareholders, Fortis Advisors sued last year after the medtech giant released reserves related to the additional $2.35 billion in milestone payments that were part of the agreement.

J&J, its Ethicon subsidiary and top corporate officers violated the merger agreement and made false promises during negotiations, according to the lawsuit.

Vice Chancellor Lori W. Will in Delaware, in a December 13 order, allowed more than half of Fortis Advisors counts against J&J to proceed, though she dismissed claims against individual J&J executives on jurisdictional grounds.

Surgical robotics is a hot sp…

DTW Weekly Podcast – Digging Deeper into Cleerly Health $43 million round

In this week’s DeviceTalks Weekly Podcast, we talk with Dr. James Min, the founder and CEO of Cleerly Health, a potentially disruptive diagnostics company that raised $43 million last week. Dr. Min explains how Cleerly Health formed from his work at Weill Cornell Medicine. But, more importantly for entrepreneurs and executives, he walks listeners through the steps he took to prepare for the fund-raising. In our next episode we’ll talk with two VCs who invested in the company to hear why Cleerly’s pitch worked.

We also talk with Jeremy Maniak, the CEO of Minnetronix, which is celebrating its 25th year in business. Maniak shares why medtech is such a draw for quality engineers who want to work for a purpose and work with the top technology. He also takes us through the process that led to Minnetronix creating its own medical device. Maniak, an electrical engineer himself, says Minnetronix will partner with OEMs to sell the device.

Chris Newmarke…

Ethicon launches curved jaw tissue sealer

[Image from Ethicon]Ethicon — part of Johnson & Johnson (NYSE:JNJ) — announced today that it launched the Enseal X1 curved jaw tissue sealer.

Cincinnati-based Ethicon developed the Enseal as a new advanced bipolar energy device designed to increase procedural efficiency and provide stronger sealing and better access to more tissue than Medtronic’s LigaSure Maryland, according to a news release.

Indications for the device include colorectal, gynecological, bariatric surgery and thoracic procedures. It includes separate seal and cut capabilities, a 360-degree continuous shaft rotation that enables easy access to targeted tissue. Ethicon’s adaptive tissue technology allows the device to continuously sense changes in the condition of tissue and respond accordingly with the optimal amount of energy to minimize lateral thermal spread.

Enseal X1 curved jaw marks the first of a series of new advanced laparoscopic bipolar devices set to launch from E…

N.J. appeals court tosses $83M pelvic mesh verdicts against J&J, Bard

A New Jersey appeals court yesterday threw out jury verdicts totaling $83 million in separate pelvic mesh lawsuits against Johnson & Johnson’s (NYSE:JNJ) Ethicon division and Becton Dickinson (NYSE:BDX) subsidiary C.R. Bard.

In both cases, Bergen County, N.J. judges erred by disallowing evidence showing that each company’s mesh product had received FDA 510 (k) clearance, according to the appeals court panel.

In the case against J&J’s Ethicon, a jury had awarded Elizabeth and Tadeusz Hrymoc $5 million in compensatory damages and $10 million in punitive damages after finding the companies liable for violating New Jersey laws on defective design of their ProLift pelvic mesh and failing to warn patients of product risk.

The jury in the case brought by Mary McGinnis and Thomas Walsh McGinnis found Bard liable for design and failure-to-warn defects under the product liability laws of North Carolina, the plaintiffs’ home state, …

DTW Podcast: Zimmer Biomet slims, Corza Medical grows in pursuit of grabbing market share

In this week’s DeviceTalks Weekly Podcast, Rich Newitter, managing director at SVB Leerink, says Zimmer Biomet’s decision to spin out its spinal and dental business will accelerate its already impressive market share grab in its core orthopedics industry.

Dewitter says CEO Bryan Hanson brings a tried-and-true diversification model used by companies like his former employer, Covidien. The spinout of the spinal and dental businesses into a NewCo will allows the company to focus more resources on selling knee and hip implants as well as building out an impressive robotics franchise and a potentially sector-leading line of digital tools and sensors.

“Zimmer has effectively gone from a share loser for almost a decade leading up to when Bryan Hanson took over to a share-taking position,” he said in an interview with Chris Newmarker, executive editor of life sciences. “This most recent quarter, their share gains have widened quite dramatically.”

In …

Corza Medical set to take on “almost monopolistic” surgical giants

Corza Medical, a new venture backed by the financial firepower of private equity giant GTCR, is looking to build a surgical tool supplier that its executive chairman Greg Lucier says can compete with “almost monopolistic” leaders in the space.

To mount the challenge, Corza acquired Surgical Specialties Corp., a supplier of surgical sutures and ophthalmic knives. Corza will use this beachhead in Westwood, Mass., to build a pipeline of acquired assets including TachoSil, a surgical patch product line Corza acquired from Takeda Pharmaceuticals last year.

In an interview with the DeviceTalks Weekly podcast, Lucier, the former CEO of spinal company NuVasive (NSDQ:NUVA) and diagnostic company Life Technologies, said management believes “there is an opening for a pretty good-sized surgical tools and technologies company to compete against the Ethicons and the Medtronics of the world.”

Lucier said the two Goliaths have reached a size that makes them “almost mono…